Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1006 AL 1020

When should orthostatic blood pressure changes be evaluated in elderly: 1st, 3rd or 5th minute?

Soysal P, Aydin AE, Koc Okudur S, Isik AT.

Arch Gerontol Geriatr. 2016 Jul-Aug;65:199-203. doi: 10.1016/j.archger.2016.03.022. Epub 2016 Apr 6.

Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

Hernando S, Gartziandia O, Herran E, Pedraz JL, Igartua M, Hernandez RM.

Nanomedicine (Lond). 2016 May;11(10):1267-85. doi: 10.2217/nnm-2016-0019. Epub 2016 Apr 14.

Glutathione S-transferase M1 polymorphisms and Parkinson's disease risk: a meta-analysis

Wang D, Zhai JX, Liu DW.

Neurol Res. 2016 Feb;38(2):144-50. doi: 10.1080/01616412.2015.1126996. Epub 2016 Mar 16.

Is it just a coincidence? Three new cases of Myasthenia Gravis associated with Parkinson's disease

Sciacca G, Nicoletti A, Mostile G, Dibilio V, Raciti L, Luca A, Reggio E, Zappia M.

Parkinsonism Relat Disord. 2016 Jul;28:166-8. doi: 10.1016/j.parkreldis.2016.04.005. Epub 2016 Apr 12.

The adaptive deep brain stimulation challenge

Arlotti M, Rosa M, Marceglia S, Barbieri S, Priori A.

Parkinsonism Relat Disord. 2016 Jul;28:12-7. doi: 10.1016/j.parkreldis.2016.03.020. Epub 2016 Apr 2.

The role of electromagnetic fields in neurological disorders

Terzi M, Ozberk B, Deniz OG, Kaplan S.

J Chem Neuroanat. 2016 Sep;75(Pt B):77-84. doi: 10.1016/j.jchemneu.2016.04.003. Epub 2016 Apr 12.

Genetic substrates of psychosis in patients with Parkinson's disease: A critical review

Lenka A, Arumugham SS, Christopher R, Pal PK.

J Neurol Sci. 2016 May 15;364:33-41. doi: 10.1016/j.jns.2016.03.005. Epub 2016 Mar 3.

Reliability and validity of an instrument for the assessment of bradykinesia

Mentzel TQ, Lieverse R, Levens A, Mentzel CL, Tenback DE, Bakker PR, Daanen HAM, van Harten PN.

Psychiatry Res. 2016 Apr 30;238:189-195. doi: 10.1016/j.psychres.2016.02.011. Epub 2016 Feb 17.

Dopamine dysregulation syndrome with psychosis in 24-hour intestinal levodopa infusion for Parkinson's disease

Ricciardi L, Espay KJ, Krikorian R, Fasano A, Espay AJ.

Parkinsonism Relat Disord. 2016 Jul;28:152-4. doi: 10.1016/j.parkreldis.2016.03.014. Epub 2016 Mar 22.

Alexithymia in Parkinson's disease: A systematic review of the literature

Assogna F, Cravello L, Orfei MD, Cellupica N, Caltagirone C, Spalletta G.

Parkinsonism Relat Disord. 2016 Jul;28:1-11. doi: 10.1016/j.parkreldis.2016.03.021. Epub 2016 Mar 30.

Neurourologic dysfunction: evaluation, surveillance and therapy

Harris CJ, Lemack GE.

Curr Opin Urol. 2016 Jul;26(4):290-4. doi: 10.1097/MOU.0000000000000290.

Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases

Lv X, Wang XX, Hou J, Fang ZZ, Wu JJ, Cao YF, Liu SW, Ge GB, Yang L.

Toxicol Appl Pharmacol. 2016 Jun 15;301:42-9. doi: 10.1016/j.taap.2016.04.009. Epub 2016 Apr 16.

Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease

Besser LM, Litvan I, Monsell SE, Mock C, Weintraub S, Zhou XH, Kukull W.

Parkinsonism Relat Disord. 2016 Jun;27:54-60. doi: 10.1016/j.parkreldis.2016.04.007. Epub 2016 Apr 9.

Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD)

Zhou ZD, Sathiyamoorthy S, Angeles DC, Tan EK.

Mol Brain. 2016 Apr 18;9:41. doi: 10.1186/s13041-016-0218-2.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD.

Mov Disord. 2016 Sep;31(9):1356-65. doi: 10.1002/mds.26611. Epub 2016 Apr 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias